[HTML][HTML] Biologics, theranostics, and personalized medicine in drug delivery systems

M Puccetti, M Pariano, A Schoubben… - Pharmacological …, 2024 - Elsevier
The progress in human disease treatment can be greatly advanced through the
implementation of nanomedicine. This approach involves targeted and cell-specific therapy …

Designing antibodies as therapeutics

PJ Carter, A Rajpal - Cell, 2022 - cell.com
Antibody therapeutics are a large and rapidly expanding drug class providing major health
benefits. We provide a snapshot of current antibody therapeutics including their formats …

Modified chitosan: insight on biomedical and industrial applications

GI Edo, E Yousif, MH Al-Mashhadani - International Journal of Biological …, 2024 - Elsevier
Abstract Chitosan (CS), a by–product of chitin deacetylation can be useful in a broad range
of purposes, to mention agriculture, pharmaceuticals, material science, food and nutrition …

[HTML][HTML] Therapeutic antibodies in medicine

P Sharma, RV Joshi, R Pritchard, K Xu, MA Eicher - Molecules, 2023 - mdpi.com
Antibody engineering has developed into a wide-reaching field, impacting a multitude of
industries, most notably healthcare and diagnostics. The seminal work on develo** the …

An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models

E Urano, Y Itoh, T Suzuki, T Sasaki… - Science translational …, 2023 - science.org
The Omicron variant continuously evolves under the humoral immune pressure exerted by
vaccination and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

Nanotherapeutics for pulmonary drug delivery: An emerging approach to overcome respiratory diseases

E Kole, K Jadhav, N Shirsath, P Dudhe… - Journal of drug delivery …, 2023 - Elsevier
Pulmonary diseases pose an immense threat to global health. Several nanotherapeutics-
based approaches aimed to tackle pulmonary ailments in recent years. The current …

Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives

G Kardas, M Panek, P Kuna, P Damiański… - Frontiers in …, 2022 - frontiersin.org
Patients with moderate-to-severe asthma may now be treated using a variety of monoclonal
antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing …

Engineered polymer–siRNA polyplexes provide effective treatment of lung inflammation

T Jeon, DC Luther, R Goswami, C Bell, H Nagaraj… - ACS …, 2023 - ACS Publications
Uncontrolled inflammation is responsible for acute and chronic diseases in the lung.
Regulating expression of pro-inflammatory genes in pulmonary tissue using small interfering …

Engineering ACE2 decoy receptors to combat viral escapability

T Arimori, N Ikemura, T Okamoto, J Takagi… - Trends in …, 2022 - cell.com
Decoy receptor proteins that trick viruses to bind to them should be resistant to viral escape
because viruses that require entry receptors cannot help but bind decoy receptors …

Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19

S Alipour, L Mahmoudi, F Ahmadi - Drug delivery and translational …, 2023 - Springer
The recent outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China has spread
rapidly around the world, leading to a widespread and urgent effort to develop and use …